Precigen
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 1998 |
| Headquarters | Germantown, Maryland , United States |
Key people | Helen Sabzevari (President and CEO) |
| Products | Gene therapy, gene editing technologies |
Precigen, Inc. (previously known as Intrexon Corporation, traded on NASDAQ under the symbol PGEN) is a U.S.-based biotech firm headed by president and CEO Helen Sabzevari.
Established in 1998 and located in Germantown, Maryland, Precigen utilizes exclusive technologies to design biological systems, allowing precise DNA-driven regulation of living cells.
History
In 2015, Intrexon completed the acquisition of Oxitec, a company specializing in genetically engineered sterile insects, for $160 million. By April 2019, Intrexon launched the subsidiary Precigen with a dedicated focus on human gene therapy. Precigen achieved FDA orphan drug designation for its CAR-T candidate PRGN-3006 aimed at treating acute myeloid leukemia. In early 2020, Intrexon underwent rebranding to become Precigen, concentrating its operations solely on human gene editing. Concurrently, Helen Sabzevari, formerly CEO of Precigen, took over leadership from Randal J. Kirk.